MD Anderson Cancer Center
1515 Holcombe Boulevard
Houston
Texas
77030
United States
Tel: 1-877-731-7527
Website: http://www.mdanderson.org/
309 articles about MD Anderson Cancer Center
-
Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT™) in Preventing Febrile Neutropenia
4/20/2021
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to treat disease and improve human health, today announced a research collaboration with researcher Robert Jenq, M.D. Professor of Genomic Medicine, at The University of Texas MD Anderson Cancer Center
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors
4/8/2021
Studies to evaluate liver and pancreatic cancers with SD-101, an investigational TLR9 agonist, in combination with checkpoint inhibition immunotherapy
-
Rankings Of Most Common And Deadly Cancer Types Will Shift Over Next Two Decades
4/7/2021
In the next two decades, rankings of incidence and death across cancer types will undergo important changes in the U.S., according to new research by Cancer Commons and the Pancreatic Cancer Action Network in collaboration with The University of Texas MD Anderson Cancer Center.
-
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
3/16/2021
- Trial will evaluate the efficacy and safety of Novartis’ targeted therapy TABRECTA ® and Puma’s NERLYNX ® in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test - This is Celcuity’s second clinical trial to treat patients diagnosed with hyperactive HER2 and c-Met signaling breast cancers with matching targeted therapies
-
MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors
2/10/2021
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecule, potent and selective KRAS inhibitors
-
UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
1/13/2021
UroGen Pharma Ltd. (Nasdaq: URGN), today announced a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer
-
MD Anderson announces fifth annual class of Andrew Sabin Family Fellows
11/12/2020
The University of Texas MD Anderson Cancer Center has named 10 early-career faculty members to the 2020 class of Andrew Sabin Family Fellows.
-
With an initial capital of $50 million, MD Anderson and partner The Focus Fund hope to invest in small biotechs with big cancer-fighting potential.
-
Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials
10/20/2020
Combination of over $50 million in committed capital along with access to cancer expertise and clinical facilities will help advance novel IND-ready candidates
-
NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA
10/13/2020
First patient injected in phase I trial evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer at The University of Texas MD Anderson Cancer Center in clinical collaboration with Nanobiotix
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Astex Pharmaceuticals and MD Anderson Announce Strategic Collaboration to Accelerate Clinical Evaluation of Therapies for Patients with Leukemia
9/8/2020
Astex Pharmaceuticals, Inc., and The University of Texas MD Anderson Cancer Center announces a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex’s pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
-
Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb® Drug Candidates
9/3/2020
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to study investigational treatments for pa
-
WAT Medical Enterprise Contributes to M.D. Anderson Cancer Center
8/31/2020
WAT Medical Enterprise has been supporting the world's cancer research. They donated part of the profits from selling EmeTerm on Amazon to the M.D. Anderson Cancer Center to support the development of global cancer. After making the donation in August 2019 , WAT Medical Enterprise will continue to support the cause of M.D. Anderso
-
Perimeter Medical Imaging Announces Expansion of ATLAS AI Project with Installation of OTISTM for AI development at Leading Cancer Care Center, MD Anderson
7/27/2020
400 Patients Expected to be Enrolled in CPRIT-Backed Artificial Intelligence Development Study in Breast Cancer
-
Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development
7/14/2020
New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines
-
Paris-based Sanofi and Houston-based The University of Texas MD Anderson Cancer Center entered a five-year strategic partnership to develop immune therapies and targeted cancer treatments.